17607-79-3Relevant articles and documents
Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias
Purohit, Meena K.,Chakka, Sai Kumar,Scovell, Iain,Neschadim, Anton,Bello, Angelica M.,Salum, Norue,Katsman, Yulia,Bareau, Madeleine C.,Branch, Donald R.,Kotra, Lakshmi P.
, p. 2739 - 2752 (2014/05/06)
Idiopathic or immune thrombocytopenia (ITP) is a serious clinical disorder involving the destruction of platelets by macrophages. Small molecule therapeutics are highly sought after to ease the burden on current therapies derived from human sources. Earlier, we discovered that dimers of five-membered heterocycles exhibited potential to inhibit phagocytosis of human RBCs by macrophages. Here, we reveal a structure-activity relationship of the bis-pyrazole class of molecules with -C-C-, -C-N- and -C-O- linkers, and their evaluation as inhibitors of phagocytosis of antibody-opsonized human RBCs as potential therapeutics for ITP. We have uncovered three potential candidates, 37, 47 and 50, all carrying a different linker connecting the two pyrazole moieties. Among these compounds, hydroxypyrazole derivative 50 is the most potent compound with an IC50 of 14 ± 9 μM for inhibiting the phagocytosis of antibody-opsonized human RBCs by macrophages. None of the compounds exhibited significant potential to induce apoptosis in peripheral blood mononuclear cells (PBMCs). Current study has revealed specific functional features, such as up to 2-atom spacer arm and alkyl substitution at one of the N1 positions of the bivalent pyrazole core to be important for the inhibitory activity.
COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
-
Page/Page column 188, (2008/06/13)
The invention encompasses compounds having formula (I-V) and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity
Kordik, Cheryl P.,Luo, Chi,Zanoni, Brian C.,Lovenberg, Timothy W.,Wilson, Sandy J.,Vaidya, Anil H.,Crooke, Jeffrey J.,Rosenthal, Daniel I.,Reitz, Allen B.
, p. 2287 - 2290 (2007/10/03)
1-Aryl-3-carboxamido-5-alkylpyrazoles were prepared based on a hit found in high-throughput screening of our corporate compound library in an assay measuring affinity for the human neuropeptide Y5 receptor. 1-(3-Trifluoromethylphenyl)-3-[N-(5-quinolinyl)carboxamido]-5-methylpyrazole (31) bound to the human neuropeptide Y5 receptor with a 80 nM IC50and was shown to inhibit cumulative food consumption 43.2% 2-6 h after ip dosing in a fasting-induced feeding model in rats.